Bayer Initiates Phase IIa ASSESS Trial of Investigational Antibody BAY 3401016 for Alport Syndrome

BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involve...

December 05, 2025 | Friday | News
Taiho Oncology Europe Announces UK Launch of Lytgobi (Futibatinib) for Eligible Patients With Locally Advanced or Metastatic Cholangiocarcinoma

Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...

December 04, 2025 | Thursday | News
VNA-318 Demonstrates Strong Target Engagement and Safety in First-in-Human Trial

VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-i...

December 03, 2025 | Wednesday | News
Cullinan’s FLT3-Targeted T Cell Engager CLN-049 Receives FDA Fast Track for R/R AML

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad populati...

December 02, 2025 | Tuesday | News
Imugene and JW Therapeutics Collaborate on Innovative CF33-CD19 and CAR-T Therapy for Solid Tumors

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlyt...

December 01, 2025 | Monday | News
Arletta Pharma Emerges from Freya Pharma Rebranding to Focus on Women’s Sexual Health

New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta but...

December 01, 2025 | Monday | News
InnoCare Pharma Doses First Patient in Global Phase II Trial of Soficitinib for Prurigo Nodularis

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced tha...

December 01, 2025 | Monday | News
Eisai and Biogen Submit Subcutaneous Lecanemab (LEQEMBI®) Application to Japan’s PMDA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuse...

December 01, 2025 | Monday | News
USPTO Grants Notice of Allowance for Enveric’s EVM401 Neuroplastogen Patent

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-m...

November 27, 2025 | Thursday | News
BriaPro Launches AI-Driven Collaboration With Receptor.AI to Design Isoform-Selective Anti-Cancer Kinase Inhibitors

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partners...

November 21, 2025 | Friday | News
Psyence BioMed Secures Sustainable, GMP-Compliant Iboga Supply Through PsyLabs to Advance Ibogaine Clinical Development

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived p...

November 21, 2025 | Friday | News
Novartis Announces Major North Carolina Expansion as Part of $23B U.S. Infrastructure Investment

Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030 Enables manufacturing...

November 21, 2025 | Friday | News
Profluent Raises $106M to Accelerate Frontier AI for Programmable Biology

Profluent, a leader in frontier AI for protein design,  announced a $106 million financing co-led by Altimeter Capital and Bezos Expeditions, with p...

November 20, 2025 | Thursday | News
Scotland Strengthens Position as Global Brain Health Innovator With New Alzheimer’s Research Centre in Aberdeen

Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s research ONE BioHub provides Scott...

November 18, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close